Characterization of monoclonal antibodies against stromelysin-3 and their use to evaluate stromelysin-3 levels in breast carcinoma by semi-quantitative immunohistochemistry
Santavicca, M.; Noël, Agnès; Chenard, M. P.et al.
1995 • In International Journal of Cancer, 64 (5), p. 336-341
[en] Stromelysin-3 (ST3) is a matrix metalloproteinase which is expressed in fibroblastic cells of most human invasive carcinomas and represents a potential new prognostic indicator. Expression of recombinant ST3 forms in Escherichia coli from cDNA constructs indicated that high levels of expression were achieved when the ST3 pro-domain was deleted. The putative mature form of ST3 thus produced and recovered from bacterial inclusion bodies was used to prepare monoclonal antibodies (MAbs) against ST3 by immunization of BALB/C mice. Ten hybridomas producing MAbs against ST3 were obtained and analyzed for their ability to detect endogenous ST3 in breast cancer and in conditioned media from human fibroblasts. One of these MAbs (5ST-4A9) was found to be suitable for the routine detection of ST3 on breast cancer tissue sections, thus opening the possibility to evaluate ST3 prognostic value in breast cancer using semi-quantitative immunohistochemistry
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Santavicca, M.
Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Chenard, M. P.
Lutz, Y.
Stoll, I.
Segain, J. P.
Rouyer, N.
Rio, M. C.
Wolf, C.
Bellocq, J. P.
Basset, P.
Language :
English
Title :
Characterization of monoclonal antibodies against stromelysin-3 and their use to evaluate stromelysin-3 levels in breast carcinoma by semi-quantitative immunohistochemistry
Publication date :
1995
Journal title :
International Journal of Cancer
ISSN :
0020-7136
eISSN :
1097-0215
Publisher :
Wiley Liss, Inc., New York, United States - New York
Ali S., Lutz Y., Bellocq J.P., Chenard‐neu M.P., Rouyer N., Metzger D. (1993) Production and characterization of monoclonal antibodies recognising defined regions of the human oestrogen receptor. Hybridoma 12:391-405.
Basset P., Bellocq J.P., Wolf C., Stoll I., Hutin P., Limacher J.M., Podhajcer O., Chenard M.P., Rio M.C., Chambon P. (1990) A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348:699-704.
Birkedal‐hansen H., Moore W.G.I., Bodden M.K., Windsor L.J., Birkedal‐Hansen B., De Carlo A., Engler J.A. (1993) Matrix metalloproteinases: a review. Crit. Rev. Oral Biol. Med. 4:7-250.
Cattoretti G., Pileri S., Parravicini C., Becker M.H.G., Poggi S., Bifulco C., Key G., D'Amato L., Sabattini E., Feudale E., Reynolds F., Gerdes J., Rilke F. (1993) Antigen unmasking on formalin‐fixed, paraffin‐embedded tissue sections. J. Pathol. 171:83-98.
Chomczynski P., Sacchi N. (1987) Single‐step method of RNA isolation by acid guanidinium thiocyanate‐phenol‐chloroform extraction. Anal. Biochem. 162:156-159.
Docherty A.J.P., O'Connell J., Crabbe T., Angal S., Murphy G. (1992) The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Trends Biotechnol. 10:200-207.
Duffy M.J., Reilly D., McDermott E., O'Higgins N., Fennelly J.J., Andreasen P. (1994) Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 74:2276-2280.
Duffy M.J., Reilly D., O'Sullivan C., O'Higgins N., Fennelly J.J., Andreasen P. (1990) Urokinase‐plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 50:6827-6829.
Elledge R.M., McGuire W.L. (1993) Prognostic factors and therapeutic decisions in axillary node‐negative breast cancer. Ann. Rev. Med. 44:201-210.
Engel G., Heseemeyer K., Auer G., Backdahl M., Eriksson E., Linder S. (1994) Correlation between stromelysin‐3 level and outcome of human breast cancer. Int. J. Cancer 58:1-7.
Foekens J.A., Schmitt M., van Putten W.L., Peters H.A., Bontenbal M., Janicke F., Klijn J.G. (1992) Prognostic value of urokinase‐type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 52:6101-6105.
Green S., Issemann I., Sheer E. (1988) A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. Nucleic Acids Res. 16:369.
Grondahl‐Hansen J., Christensen I.J., Rosenquist C., Brunner N., Mouridsen H.T., Dano K., Blichert‐Toft M. (1993) High levels of urokinase‐type plasminogen activator and its inhibitor PAI‐1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53:2513-2521.
Hahnel E., Harvey J.M., Joyce R., Robbins P.D., Sterrett G.F., Hahnel R. (1993) Stromelysin‐3 expression in breast cancer biopsies: clinico‐pathological correlations. Int. J. Cancer 55:771-774.
Harris J.R., Lippman M.E., Veronesi U., Willett W. (1992) Breast cancer (1). New Engl. J. Med. 327:3-28.
Helzlsouer K.J. (1994) Epidemiology, prevention, and early detection of breast cancer. Curr. Opin. Oncol. 6:541-548.
Kawami H., Yoshida K., Ohsaki A., Kuroi K., Nishiyama M., Toge T. (1993) Stromelysin‐3 mRNA expression and malignancy: comparison with clinicopathological features and type IV collagenase mRNA expression in breast tumors. Anticancer Res. 13:2319-2324.
Lippman M.E. (1993) The development of biological therapies for breast cancer. Science 259:631-632.
Matrisian L.M. (1992) The matrix‐degrading metalloproteinases. Bioessays 14:455-463.
Murphy G., Segain J.P., O'Shea M., Cockett M., Ioannou C., Lefebvre O., Chambon P., Basset P. (1993) The 28‐kDa N‐terminal domain of mouse stromelysin‐3 has the general properties of a weak metalloproteinase. J. biol. Chem. 268:15435-15441.
Rouyer N., Wolf C., Chenard M.P., Rio M.C., Bellocq J.P., Chambon P., Basset P. (1994) Stromelysin‐3 gene expression in human cancer: an overview. Invasion Metastasis 14:269-275.
Stetler‐Stevenson W.G., Aznavoorian S., Liotta L.A. (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annual Review of Cell Biology 9:541-573.
Studier F.W., Rosenberg A.H., Dunn J.J., Dubendorff J.W. (1990) Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 185:60-89.
Wolf C., Rouyer N., Lutz Y., Adida C., Loriot M., Belloco J.P., Chambon P., Basset P. (1993) Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc. nat. Acad. Sci. (Wash.) 90:1843-1847.
